Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, Saar Gill|Journal of Clinical Investigation|2016Cited by 554
An NK-like CAR T cell transition in CAR T cell dysfunctionCharly R. Good, Carl H. June, M. Ángela Aznar et al.|Cell|2021Cited by 398
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Marco Ruella, Yong Gu Lee et al.|Cancer Discovery|2020Cited by 297
Catch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesMarco Ruella, Marcela V. Maus|Computational and Structural Biotechnology Journal|2016Cited by 281